-
1
Rule of Prevention: a potential framework to evaluate preventive interventions for rare diseases
Published 2023-12-01“…Journal of Market Access & Health Policy…”
Get full text
Article -
2
Why “American Patients First” is likely to raise drug prices outside of the United States
Published 2019-01-01“…Journal of Market Access & Health Policy…”
Get full text
Article -
3
An Inclusive Civil Society Dialogue for Successful Implementation of the EU HTA Regulation: Call to Action to Ensure Appropriate Involvement of Stakeholders and Collaborators
Published 2024-03-01“…Journal of Market Access & Health Policy…”
Get full text
Article -
4
Health economic evaluation of gene replacement therapies: methodological issues and recommendations
Published 2020-01-01“…Journal of Market Access & Health Policy…”
Get full text
Article -
5
Tendering and biosimilars: what role for value-added services?
Published 2020-01-01“…Journal of Market Access & Health Policy…”
Get full text
Article -
6
The role of stakeholder involvement in the evolving EU HTA process: Insights generated through the European Access Academy’s multi-stakeholder pre-convention questionnaire
Published 2023-12-01“…Journal of Market Access & Health Policy…”
Get full text
Article -
7
Economic evaluation of biosimilars for reimbursement purposes – what, when, how?
Published 2020-01-01“…Journal of Market Access & Health Policy…”
Get full text
Article